Abstract 4841
Background
Recent population studies have shown an increase in cancer rates in patients after burn injury over a 30-year follow-up period. This work aims to understand the mediators and mechanisms that lead to cancer susceptibility after acute burn.
Methods
In silico analytics with Watson for Drug Discovery were performed to interrogate networks and pathways in common between burn injury and cancer to better understand the possible mechanistic links. We then useda murine non-severe burn injury model (injury to ∼ 6% body surface area) with subsequent tumor susceptibility evaluation using B16 melanoma challenge 4 weeks after the burn injury. Primary tumor growth (n = 10) and metastasis (n = 11-13) were assessed compared to sham controls.
Results
Network analysis highlighted multiple overlapping pathways important in burn repair and in tumors. In particular, the evidence suggested links to pathways important in the immune response to burn injury (including well characterized pro-inflammatory genes such as IL-6 and TNF-α) and matrix remodeling (such as MMP9) to metastasis. In the murine model, at four weeks after burn injury, primary tumor growth was unaffected (mean volume 353.7mm3± 235.4 vs 256.8mm3± 122.6, burn injury and control respectively, p = 0.32). However, mean number of metastases in burn injury mice was significantly increased (7.7± 4.1 compared with 2.6 ± 1.8 for control mice (p = 0.0015)), and there was a trend for increased metastatic tumor volume (mean volume 2.7 ± 1.2 compared with 1.6 ±1.3 cm3 respectively, p = 0.08) after burn injury.
Conclusions
This work suggests burn injury increases cancer susceptibility, specifically through increased number and size of metastases. Further work to delineate the mechanism, potentially through modulation of in silico-identified immune system and metastasis pathways, may provide potential to improve long-term health outcomes for patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Fiona Woods Institute.
Funding
IBM Watson Health.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3140 - Phase 2 study of olaparib in previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) or homologous recombination repair deficiency (HRD): LYNK-002
Presenter: David Hyman
Session: Poster Display session 3
Resources:
Abstract
2655 - The K-BASKET trial: A prospective phase II biomarker-driven multiple basket trial in Korean solid cancer patients.
Presenter: Seul Kim
Session: Poster Display session 3
Resources:
Abstract
5938 - Cambridge Liquid biopsy “CALIBRATION” study: Can changes in circulating tumour DNA (ctDNA) predict durable tumour responses in patients with advanced oesophageal cancer receiving MEDI4736?
Presenter: Constanza Linossi
Session: Poster Display session 3
Resources:
Abstract
3799 - Validation of a tumour mutational burden workflow on routine histological samples of colorectal cancer and assessment of a cohort with synchronous hepatic metastases
Presenter: Andrea Mafficini
Session: Poster Display session 3
Resources:
Abstract
4647 - Microsatellite Instability Testing and Lynch Syndrome Screening For Colorectal Cancer Patients Through Tumor Sequencing
Presenter: Li Liu
Session: Poster Display session 3
Resources:
Abstract
3231 - "Liquid Withdarw" technique in CT-guided cutting needle lung biopsy: decreased incidence of complications and increased tissue amount for lung cancer molecular testing.
Presenter: Xue Wang
Session: Poster Display session 3
Resources:
Abstract
3282 - WGS Implementation in standard cancer Diagnostics for Every cancer patient (WIDE)
Presenter: Paul Roepman
Session: Poster Display session 3
Resources:
Abstract
5905 - Known and unknown gene fusion detection capabilities of solid tumor laboratories conducting next generation sequencing in 6 countries
Presenter: Steph Finucane
Session: Poster Display session 3
Resources:
Abstract
4238 - Clinical and Analytical Accuracy of a 523 Gene Panel Next-Generation Sequencing (NGS) Assay on Formalin-Fixed Paraffin-Embedded (FFPE) Solid Tumor Samples
Presenter: Ina Deras
Session: Poster Display session 3
Resources:
Abstract
2493 - Methylation analysis of MLH1 using droplet digital PCR and methylation sensitive restriction enzyme.
Presenter: Celine De Rop
Session: Poster Display session 3
Resources:
Abstract